Apnimed will apply the IPO proceeds toward the regulatory process and launch plans of Oxnimbi, a once-nightly pill developed for obstructive sleep apnea. This drug is under FDA review with a February 2027 target date for a regulatory decision.
Apnimed’s obstructive sleep apnea drug reduced breathing interruptions in a Phase 3 clinical trial. The once-nightly pill, which is based on research from Brigham and Women’s Hospital, activates muscles that keep the upper airway open during sleep.
Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.